By Colin Kellaher
Shares of Seagen Inc. rose 5% in premarket trading Thursday after The Wall Street Journal reported that Merck & Co. is closing in on a takeover of the biotechnology company in a deal that could be worth $40 billion or more.
The Journal, which last month reported that Merck was circling Seagen, said the companies are discussing a purchase price topping $200 a share.
That is well above Wednesday's closing price of $175.13 and more than 35% above the Seattle company's closing price of share price of $146.78 on June 16, before the initial report from The Journal.
Shares of Seattle-based Seagen, which currently sports a market capitalization of around $32.5 billion, were recently changing hands at $183.87, up 5%, in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
07-07-22 0616ET